Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/32306
Title: The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis
Authors: Freedberg, Kenneth A.
Possas, Cristina
Deeks, Steven
Ross, Anna Laura
Rosettie, Katherine L.
Mascio, Michele Di
Collins, Chris
Walensky, Rochelle P.
Yazdanpanah, Yazdan
Affilliation: Divisions of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Boston, USA / Harvard TH Chan School of Public Health. Department of Health Policy and Management. Boston, USA.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brazil.
San Francisco General Hospital. University of California San Francisco. Department of Medicine.San Francisco, CA, USA / National Institutes of Health. Department of Health and Human Services. Bethesda, MD, USA.
International AIDS Society, Geneva, Switzerland / ANRS. International and Scientific Relations Office. Paris, France.
National Institute of Allergy and Infectious Diseases. Division of Clinical Research. National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
National Institute of Allergy and Infectious Diseases. Division of Clinical Research. National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Community Mobilization Division. Geneva, Switzerland.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Community Mobilization Division. Geneva, Switzerland / Brigham and Women's Hospital.Division of Infectious Disease. Boston, MA, USA.
INSERM / Université Paris Diderot, IAM. Sorbonne Paris Cité / Hôpital Bichat. Services de Maladies Infectieuses et Tropicales. Paris, France.
Abstract: The research agenda towards an HIV cure is building rapidly. In this article, we discuss the reasons for and methodological approach to using mathematical modelling and cost-effectiveness analysis in this agenda. We provide a brief description of the proof of concept for cure and the current directions of cure research. We then review the types of clinical economic evaluations, including cost analysis, cost-benefit analysis and cost-effectiveness analysis. We describe the use of mathematical modelling and cost-effectiveness analysis early in the HIV epidemic as well as in the era of combination antiretroviral therapy. We then highlight the novel methodology of Value of Information (VOI) analysis and its potential role in the planning of clinical trials. We close with recommendations for modelling and cost-effectiveness analysis in the HIV cure agenda.
Keywords: HIV/AIDS
Cost-effectiveness
Cure
Mathematical modeling
Issue Date: 2015
Citation: FREEDBERG, Kenneth A. et al. The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis. Journal Of Virus Eradication, London, v. 4, n. 1, p. 245-249, 2015.
Description: For the International AIDS Society Working Group on Cost-Effectiveness: Towards an HIV Cure Initiative.
ISSN: 2055-6640
Copyright: open access
Appears in Collections:INI - Artigos de Periódicos
Biomanguinhos - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
F124-jve-1-245.pdf78.37 kBAdobe PDFView/Open


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.